Lexicon Pharmaceuticals (LXRX) FCF Margin (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) reported FCF Margin of 69.8% for Q1 2026, up 339913.0% year-over-year from N/an in Q1 2025, and up 77.75% on a QoQ basis from 313.73% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) has 16 years of FCF Margin data on file, last reported at 69.8% in Q1 2026.
- Quarterly FCF Margin rose 339913.0% year-over-year to 69.8% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 55.72% (up 48399.0% YoY) and the FY2025 annual result came in at 136.24%, up 44229.0% from the prior year.
- FCF Margin rose to 69.8% in Q1 2026 per LXRX's latest filing, from 313.73% in the prior quarter.
- Across five years, FCF Margin topped out at 58.87% in Q2 2025 and bottomed at 25741.98% in Q3 2023.
- The 4-year median for FCF Margin is 3021.92% (2024), against an average of 4961.77%.
- The widest annual swing landed in 2024, when FCF Margin surged 2266049 bps; it then plunged 23101 bps in 2025.
- Tracing LXRX's FCF Margin over 4 years: stood at 6598.96% in 2023, then jumped by 99 bps to 82.72% in 2024, then slumped by 279 bps to 313.73% in 2025, then jumped by 78 bps to 69.8% in 2026.
- Per Business Quant, the three latest LXRX FCF Margin figures stand at 69.8% (Q1 2026), 313.73% (Q4 2025), and 168.05% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.17% |
| 10 | Lexicon Pharmaceuticals | 872.52 Mn | 701.87 Mn | 20.99 Mn | -69.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.80% |
| Dec 31, 2025 | -313.73% |
| Sep 30, 2025 | -168.05% |
| Jun 30, 2025 | 58.87% |
| Mar 31, 2025 | -3,468.94% |
| Dec 31, 2024 | -82.72% |
| Sep 30, 2024 | -3,081.49% |
| Jun 30, 2024 | -2,962.36% |
| Mar 31, 2024 | -5,043.92% |
| Dec 31, 2023 | -6,598.96% |
| Sep 30, 2023 | -25,741.98% |
| Jun 30, 2023 | -12,068.14% |
| Dec 31, 2021 | 8,046.13% |
| Jun 30, 2021 | -9,755.13% |
| Mar 31, 2021 | -93,322.22% |
| Dec 31, 2020 | 144.31% |
| Jun 30, 2020 | -185,192.00% |
| Mar 31, 2020 | -275.71% |
| Dec 31, 2019 | -279.26% |
| Sep 30, 2019 | 64.76% |
| Jun 30, 2019 | -277.84% |
| Mar 31, 2019 | -1,053.30% |
| Dec 31, 2018 | -159.13% |
| Sep 30, 2018 | -318.46% |
| Jun 30, 2018 | -380.77% |
| Mar 31, 2018 | -184.50% |
| Dec 31, 2017 | -99.26% |
| Sep 30, 2017 | -122.94% |
| Jun 30, 2017 | -267.20% |
| Mar 31, 2017 | -476.49% |
| Dec 31, 2016 | -212.44% |
| Jun 30, 2016 | -238.39% |
| Mar 31, 2016 | -350.52% |
| Dec 31, 2015 | 208.74% |
| Sep 30, 2015 | -4,535.16% |
| Jun 30, 2015 | -8,681.12% |
| Mar 31, 2015 | -1,311.50% |
| Dec 31, 2014 | -20.91% |
| Sep 30, 2014 | -5,058.95% |
| Jun 30, 2014 | -2,909.17% |
| Mar 31, 2014 | -10,955.60% |
| Dec 31, 2013 | -1,557.16% |
| Sep 30, 2013 | -10,169.33% |
| Jun 30, 2013 | -10,061.21% |
| Mar 31, 2013 | -6,975.00% |
| Dec 31, 2012 | -9,424.31% |
| Sep 30, 2012 | -6,752.42% |
| Jun 30, 2012 | -11,081.41% |
| Mar 31, 2012 | -9,078.67% |
| Dec 31, 2011 | -6,618.08% |
| Sep 30, 2011 | -5,746.48% |
| Jun 30, 2011 | -4,323.78% |
| Mar 31, 2011 | -3,699.16% |
| Dec 31, 2010 | -1,569.59% |
| Sep 30, 2010 | -2,426.12% |